DE60131856D1 - Motif auf basis van leucin und clostridium neurotoxine - Google Patents

Motif auf basis van leucin und clostridium neurotoxine

Info

Publication number
DE60131856D1
DE60131856D1 DE60131856T DE60131856T DE60131856D1 DE 60131856 D1 DE60131856 D1 DE 60131856D1 DE 60131856 T DE60131856 T DE 60131856T DE 60131856 T DE60131856 T DE 60131856T DE 60131856 D1 DE60131856 D1 DE 60131856D1
Authority
DE
Germany
Prior art keywords
neurotoxine
leucin
clostridium
van
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131856T
Other languages
English (en)
Other versions
DE60131856T2 (de
Inventor
Lance E Steward
Ester Fernandez-Salas
Todd M Herrington
Kei Roger Aoki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24487624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60131856(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of DE60131856D1 publication Critical patent/DE60131856D1/de
Publication of DE60131856T2 publication Critical patent/DE60131856T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60131856T 2000-07-21 2001-07-20 Motiv auf Basis von Leucin und Clostridium-Neurotoxine Expired - Lifetime DE60131856T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US620840 2000-07-21
US09/620,840 US6903187B1 (en) 2000-07-21 2000-07-21 Leucine-based motif and clostridial neurotoxins
PCT/US2001/023122 WO2002008268A2 (en) 2000-07-21 2001-07-20 Leucine-based motif and clostridial neurotoxins

Publications (2)

Publication Number Publication Date
DE60131856D1 true DE60131856D1 (de) 2008-01-24
DE60131856T2 DE60131856T2 (de) 2008-11-27

Family

ID=24487624

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131856T Expired - Lifetime DE60131856T2 (de) 2000-07-21 2001-07-20 Motiv auf Basis von Leucin und Clostridium-Neurotoxine

Country Status (14)

Country Link
US (11) US6903187B1 (de)
EP (3) EP1309618B1 (de)
JP (1) JP4818565B2 (de)
KR (1) KR20030033000A (de)
CN (1) CN100457777C (de)
AT (1) ATE380824T1 (de)
AU (2) AU8070301A (de)
BR (1) BR0112715A (de)
CA (1) CA2416988C (de)
DE (1) DE60131856T2 (de)
ES (1) ES2296782T3 (de)
MX (1) MXPA03000576A (de)
NZ (1) NZ523662A (de)
WO (1) WO2002008268A2 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153397B2 (en) * 1993-09-21 2012-04-10 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
EP0878552A1 (de) * 1997-05-13 1998-11-18 Erasmus Universiteit Rotterdam Molekularer Nachweis von chromosomalen Veränderungen
CA2327542C (en) * 1998-05-04 2011-11-22 Dako A/S Method and probes for the detection of chromosome aberrations
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7691983B2 (en) * 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7223577B2 (en) * 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US20040226556A1 (en) * 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US8398997B2 (en) * 2004-03-03 2013-03-19 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US7399607B2 (en) * 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
EP1824971B1 (de) 2004-11-22 2016-01-13 New York University Genetisch veränderte clostridiengene, durch die veränderten gene kodierte proteine und deren verwendungen
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
JP2008532549A (ja) 2005-03-15 2008-08-21 アラーガン、インコーポレイテッド 内因性クロストリジウム毒素受容体系に対する増大した標的能力を有する修飾クロストリジウム毒素
AU2006315117A1 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
AU2007347781B2 (en) 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
AU2007340162B2 (en) * 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
BRPI0720729A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP4166107A1 (de) 2008-05-09 2023-04-19 Nuvaira, Inc. Systeme, anordnungen und verfahren zur behandlung eines bronchialbaums
CN102131823A (zh) 2008-08-29 2011-07-20 德国麦氏大药厂 具有改变的持久性的梭状芽孢杆菌神经毒素
GB0903913D0 (en) * 2009-03-06 2009-04-22 Medical Res Council Compositions and methods
PT3281953T (pt) * 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
CN102471765B9 (zh) 2009-07-02 2016-07-27 莫茨制药有限及两合公司 显示出缩短的生物学活性的神经毒素
JP2013501771A (ja) * 2009-08-12 2013-01-17 メディカル リサーチ カウンシル 複合体形成系
WO2011041779A1 (en) 2009-10-02 2011-04-07 Allergan, Inc. In vitro method of determining changes in a protein environment
EP4193948A1 (de) 2009-10-27 2023-06-14 Nuvaira, Inc. Freisetzungsvorrichtungen mit kühlbaren energieemissionsanordnungen
US9149328B2 (en) 2009-11-11 2015-10-06 Holaira, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
KR20120107988A (ko) 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
EP2528941A4 (de) * 2010-01-25 2013-05-29 Univ New York Für verkehrsstudien und neuronale verabreichung manipulierte rekombinante derivate aus botulinum-neurotoxinen
PT2684890T (pt) 2010-01-25 2016-07-28 Allergan Inc Métodos de conversão intracelular de proteínas de cadeia única na sua forma de cadeia dupla
WO2011103465A2 (en) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
JP6148979B2 (ja) 2010-05-20 2017-06-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 分解性クロストリジウム毒素
US20120251574A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20140170133A1 (en) * 2011-08-04 2014-06-19 Jurgen Frevert Alteration of proteolytic cleavage of botulinum neurotoxins
ES2638333T3 (es) * 2011-11-09 2017-10-19 Merz Pharma Gmbh & Co. Kgaa Neurotoxinas que presentan una actividad biológica reducida
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
EP2928912A1 (de) * 2012-12-05 2015-10-14 Merz Pharma GmbH & Co. KGaA Neuartige rekombinante clostridienneurotoxine mit verbesserter membranlokalisierung
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP3027641A1 (de) 2013-07-30 2016-06-08 Merz Pharma GmbH & Co. KGaA Verfahren zur herstellung einer hochreinen neurotoxischen komponente eines botulinumtoxins und verwendungen davon
WO2015024503A1 (en) * 2013-08-21 2015-02-26 The Hong Kong Polytechnic University Engineering clostridia neurotoxins with elevated catalytic activity
ES2704237T3 (es) 2014-03-05 2019-03-15 Merz Pharma Gmbh & Co Kgaa Nuevas neurotoxinas clostridiales recombinantes con un aumento de la duración del efecto
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
JP7017932B2 (ja) 2014-12-09 2022-02-09 ニューヨーク・ユニバーシティ クロストリジウム神経毒融合タンパク質、プロペプチド融合体、それらの発現及び使用方法
EP3822286A1 (de) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Kationische neurotoxine
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
WO2017125487A1 (en) 2016-01-20 2017-07-27 Merz Pharma Gmbh & Co. Kgaa Novel recombinant clostridial neurotoxins with increased duration of effect
BR112018014445A2 (pt) 2016-03-02 2018-12-11 Merz Pharma Gmbh & Co Kgaa composição que compreende toxina botulínica
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
US20210277071A1 (en) 2016-09-29 2021-09-09 Ipsen Biopharm Limited Hybrid neurotoxins
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3642222A1 (de) 2017-06-20 2020-04-29 Merz Pharma GmbH & Co. KGaA Neuartiges rekombinantes botulinumtoxin mit erhöhter wirkdauer
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
WO2019101308A1 (en) 2017-11-22 2019-05-31 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
WO2019243376A1 (en) 2018-06-18 2019-12-26 Ipsen Biopharm Limited Intramuscular injection of botulinum toxin for the treatment of vulvodynia
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
BR112021005774A2 (pt) 2018-09-28 2021-07-06 Inst Of Molecular And Cell Biology Biomedical Sciences Insts ensaios de neurotoxina de clostridiana à base de célula
EP3883950A4 (de) * 2018-11-21 2022-09-07 The Regents of the University of Colorado, a body corporate Proteine zur blockierung der freisetzung von neurotransmittern
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201907016D0 (en) 2019-05-17 2019-07-03 Ipsen Biopharm Ltd Screening method to determine suitability for participation in a clinical trial
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US4932936A (en) 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) * 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5174468A (en) * 1991-01-30 1992-12-29 Holderman Lisa A Trash organizer
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
WO1994015629A1 (en) 1993-01-15 1994-07-21 Associated Synapse Biologics Method for treating myofascial pain syndrome
JPH08506033A (ja) 1993-01-27 1996-07-02 インステント インコーポレーテッド 血管及び冠状脈ステント
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
EP1086702B1 (de) 1994-05-09 2005-04-13 BINDER, William J. Präsynaptische Neurotoxine gegen Migränekopfschmerzen
US5714986A (en) 1995-01-31 1998-02-03 Compag Computer Corporation Run slice line draw engine with enhanced line configurations
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5837263A (en) * 1995-05-19 1998-11-17 The Regents Of The University Of California Leptospira membrane proteins
WO1996039166A1 (en) * 1995-06-06 1996-12-12 Wisconsin Alumni Research Foundation Analogs of botulinum toxin and pharmaceutical compositions of botulinum toxin
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5939070A (en) 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
CA2505933C (en) * 1997-07-15 2008-09-30 Richard A. Schmidt Use of botulinum toxin for treating urinary incontinence
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
JP3691221B2 (ja) * 1997-09-24 2005-09-07 三菱電機株式会社 レーザ加工方法
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
SE9801516D0 (sv) * 1998-04-30 1998-04-30 Maria Carlsson M100907/4-Piperidinemethanol derivatives for autism
US6133915A (en) * 1998-06-17 2000-10-17 Microsoft Corporation System and method for customizing controls on a toolbar
AU4641299A (en) * 1998-07-22 2000-02-14 Agricultural Research Council Vaccine comprising a non-toxic immunogenic derivative of (clostridium botulinum)type d neurotoxin
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6358513B1 (en) * 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6328977B1 (en) * 2000-02-22 2001-12-11 Allergan Sales, Inc. Method for treating hyperparathyroidism
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7163649B2 (en) * 2001-07-09 2007-01-16 The United States Of America As Represented By The Secretary Of Commerce Minimizing spatial-dispersion-induced birefringence

Also Published As

Publication number Publication date
US6903187B1 (en) 2005-06-07
US20080177037A1 (en) 2008-07-24
US7534863B2 (en) 2009-05-19
KR20030033000A (ko) 2003-04-26
EP2174949A2 (de) 2010-04-14
CN100457777C (zh) 2009-02-04
US20050276820A1 (en) 2005-12-15
US7393925B2 (en) 2008-07-01
AU8070301A (en) 2002-02-05
US20080214781A1 (en) 2008-09-04
US7691974B2 (en) 2010-04-06
AU2001280703B2 (en) 2006-08-31
ES2296782T3 (es) 2008-05-01
CA2416988C (en) 2013-02-12
US20080177042A1 (en) 2008-07-24
US7705124B2 (en) 2010-04-27
CA2416988A1 (en) 2002-01-31
US20090118475A1 (en) 2009-05-07
US8206723B2 (en) 2012-06-26
US20090202591A1 (en) 2009-08-13
EP1849801A1 (de) 2007-10-31
ATE380824T1 (de) 2007-12-15
JP4818565B2 (ja) 2011-11-16
EP1309618A2 (de) 2003-05-14
US7705125B2 (en) 2010-04-27
WO2002008268A2 (en) 2002-01-31
NZ523662A (en) 2005-03-24
DE60131856T2 (de) 2008-11-27
EP1309618B1 (de) 2007-12-12
JP2005517627A (ja) 2005-06-16
MXPA03000576A (es) 2004-04-05
EP2174949A3 (de) 2014-02-19
CN1461308A (zh) 2003-12-10
US20050260230A1 (en) 2005-11-24
US20080177041A1 (en) 2008-07-24
WO2002008268A3 (en) 2003-02-20
US20030027752A1 (en) 2003-02-06
US7723480B2 (en) 2010-05-25
BR0112715A (pt) 2003-05-20
US20080194797A1 (en) 2008-08-14
US7671177B2 (en) 2010-03-02

Similar Documents

Publication Publication Date Title
DE60131856D1 (de) Motif auf basis van leucin und clostridium neurotoxine
DK0698105T3 (da) Nukleotidsekvenser til styring af ekspressionen af DNAsekvenser i en værtscelle
ECSP034565A (es) Lamina para el control de plagas
ATE346928T1 (de) Aus nematoden extrahierte serinprotease- inhibitoren und die koagulation hemmende proteine
ATE317441T1 (de) Cathepsin-02-protease
ATE308550T1 (de) Verwendungen von sulfatierten fuko- oligosacchariden zum pflanzenschutz
ATE449106T1 (de) Isoliertes, dimerisches fibroblasten- aktivierendes protein alpha und anwendungen desselben
WO2002024899A3 (en) Improved system for regulation of transgene expression
DK1472344T3 (da) Bakteriofaglysin
DE60132177D1 (en) Aminosäure-derivate als hiv aspartyl-protease-inhibitoren
NO975447L (no) Dynamisk trykksensor
DE60104485D1 (de) Pyrotechnischer Aktuator mit verformbarer Membran
ATE357512T1 (de) Ralstonia ahl-acylase gen
DK1017793T3 (da) Nye cyclomaltodextrin-glucanotransferasevarianter
ATE352460T1 (de) Verbesserungen für eine sicherheitsanordnung für ein fahrzeug oder diese betreffend
BR0114065A (pt) Triazolo-epotilonas
FR2793385B1 (fr) Agrafe de palissage autocassante
BR0011278A (pt) Sistema de freio eletronicamente regulado
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
ES2188530T3 (es) Dispositivo de seguridad y usos del mismo.
SE0000127D0 (sv) Lågtryck destilations system L.P.D.S.
KR940019854A (ko) 인지질 분해효소 에이 투(phospholipase A_2) 저해물질을 생성하는 미생물
BR9900600A (pt) Sistema de reconhecimento de folha.
ATE512506T1 (de) Verstärkervorrichtung
ITRM950131V0 (it) Sensore di differenza di pressione.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ALLERGAN, INC., IRVINE, CALIF., US

8363 Opposition against the patent